To further understand the underlying mechanism of the association between PTPRD/PTPRT mutation and better clinical outcomes in NSCLC patients who received ICBs therapy, the impact of PTPRD/PTPRT mutation on TMB or immune-related gene signatures was explored. This evidence concerns the gene PTPRD and non-small cell lung carcinoma.